Charting a new course in inflammatory and autoimmune disease medicine.
Navigator Medicines is a clinical-stage biotech advancing bispecific antibodies anchored in OX40L inhibition. Our exceptional team is working to bring new hope to people living with complex inflammatory disorders and autoimmune diseases.
We develop bispecific antibodies that simultaneously block OX40L and TNFα, targeting two key drivers of inflammation to deliver better, longer-lasting results for patients.
News
November 20, 2025
Navigator Medicines Completes Last Participant Last Visit (LPLV) in Phase 1b Trial of NAV-240, an OX40L and Anti-TNFα Bispecific Antibody for Autoimmune Diseases
>> READ MORE
March 27, 2026
Navigator Medicines Advances NAV-240 into Phase 2a and NAV-242 into the Clinic, Supported by New Positive Data Presented at American Academy of Dermatology (AAD) Annual Meeting 2026
>> READ MORE
January 8, 2026
Navigator Medicines Accelerates Anti OX-40L and TNFα Bispecific Antibody Clinical Development Pipeline into Phase 2a and First-in-Human Trials
>> READ MORE